Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

rPCI-24781 is an orally-bioavailable histone deacetylase inhibitor that is in multiple clinical trials. We are conducting a Phase I trial in patients with advanced solid tumors, a Phase I/II trial in sarcoma patients (in combination with doxorubicin, an anti tumor agent) and a Phase I/II trial  testing PCI-24781 in patients with relapsed or refractory Non-Hodgkin's lymphoma. Currently we are enrolling the final follicular lymphoma patients in the Phase II portion of this trial and expect to complete enrollment by Q4 of calendar 2011.  Our collaboration partner for ex-US development, Servier, has five Phase I and I/II trials ongoing in Europe in lymphomas and solid tumors.

Conference Call and Webcast DetailsThe Company will hold a conference call today at 4:30 p.m. EDT. To participate in the conference call, please dial 1-877-407-8133 for domestic callers and 1-201-689-8040 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at www.pharmacyclics.com.

For further questions please contact Ramses Erdtmann, VP Finance at: 408-215-3325

Non-Hodgkin's Lymphoma (NHL) Market There are significant and distinct areas of unmet medical need across the NHL subtypes.  Within the indolent lymphomas, we believe a need exists for active therapies that avoid the toxicities typically seen with conventional chemotherapies. Such active therapies are needed as part of effective combinations early in the course of treatment, and also as effective single-agent treatments later in the course of disease progression.  In particular, drugs which are well tolerated and which do not limit subsequent treatment options b
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... , TUESDAY, Feb. 1 (HealthDay News) -- Confusion caused ... number of the painkiller prescription errors that occur in ... was nearly three per 1,000 prescriptions in hospitals, and ... study found. Researchers reviewed 714,290 orders for painkillers ...
... brain scans showing neural reactions can predict behavior change ... scanned. Emily Falk, director of University of Michigan,s ... the brain activity of 28 heavy smokers to investigate ... ability to quit smoking. The smokers were recruited from ...
... 1 (HealthDay News) -- There isn,t sufficient evidence to recommend ... neck arteries that could cause a stroke. That,s one ... clogged arteries, released Jan. 31 by the American Heart Association, ... of stroke increases when blood flow to the brain is ...
... By Ellin Holohan HealthDay Reporter , TUESDAY, ... children have their tonsils removed, an analysis of four decades ... that 50 percent of the children in the studies gained ... to study lead author Dr. Anita Jeyakumar. While not "hugely ...
... mean more targeted breast biopsies for patients with early ... those patients from undergoing a second breast cancer surgery, ... breast cancer undergo a sentinel lymph node biopsy to ... Sever, lead author of the study. Ultrasound, on ...
... Reporter , MONDAY, Jan. 31 (HealthDay News) -- With ... dogs can sniff out buried earthquake victims. They can ... detect colorectal cancer, Japanese researchers suggest. Researchers from ... 8-year-old female Labrador retriever named Marine is able to ...
Cached Medicine News:Health News:Look-and-Sound-Alike Names Account for Many Painkiller Prescription Errors 2Health News:Brain scans predict likely success when it comes to quitting smoking 2Health News:Experts Issue Guidelines on Care of Clogged Neck Arteries 2Health News:Experts Issue Guidelines on Care of Clogged Neck Arteries 3Health News:Children May Pack on Pounds After Tonsillectomy 2Health News:Children May Pack on Pounds After Tonsillectomy 3Health News:Microbubble ultrasound and breast biopsies 2Health News:Trained Labrador Can Sniff Out Colon Cancer, Researchers Say 2Health News:Trained Labrador Can Sniff Out Colon Cancer, Researchers Say 3Health News:Trained Labrador Can Sniff Out Colon Cancer, Researchers Say 4
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Filters are ideal for PCR ... for any work where aerosol ... designed for pipetting DNA/RNA solutions, ... other. For applications requiring absolute ...
Medicine Products: